Display Settings:


Send to:

Choose Destination
Hum Gene Ther. 2009 Aug;20(8):796-806. doi: 10.1089/hum.2009.094.

Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies.

Author information

  • 1Department of Pediatrics, Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610, USA.


The ability of recombinant adeno-associated viral (rAAV) vectors to exhibit minimal immunogenicity and little to no toxicity or inflammation while eliciting robust, multiyear gene expression in vivo are only a few of the salient features that make them ideally suited for many gene therapy applications. A major hurdle for the use of rAAV in sizeable research and clinical applications is the lack of efficient and versatile large-scale production systems. Continued progression toward flexible, scalable production techniques is a prerequisite to support human clinical evaluation of these novel biotherapeutics. This review examines the current state of large-scale production methods that employ the herpes simplex virus type 1 (HSV) platform to produce rAAV vectors for gene delivery. Improvements have substantially advanced the HSV/AAV hybrid method for large-scale rAAV manufacture, facilitating the generation of highly potent, clinical-grade purity rAAV vector stocks. At least one human clinical trial employing rAAV generated via rHSV helper-assisted replication is poised to commence, highlighting the advances and relevance of this production method.

[PubMed - indexed for MEDLINE]
Free PMC Article

Images from this publication.See all images (2)Free text

FIG. 1.
FIG. 2.
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Mary Ann Liebert, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk